Clinical Trial

An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects

Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Summary
An extension of Global Phase III open-label, multicenter designed to evaluate the Long-term safety and efficacy of study drug for the treatment of the MPS II.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2022-10-21; most recent amendment 2026-01-19.
Status change: Not Yet Recruiting → Enrolling by Invitation 2023-02-21
Trial Details
NCT Number NCT05594992
Lead Sponsor JCR Pharmaceuticals Co., Ltd.
Conditions Mucopolysaccharidosis II
Enrollment 80 participants
Start Date 2023-02-22
Primary Completion 2028-02-28 (estimated)
Study Completion 2028-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-01-21